Colorectal cancer (CRC) is one of the most common cancers globally and is associated with a high
mortality rate. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in normal
intestinal tissue function, but has also been implicated in the development of CRC. MicroRNAs (miRNAs) have
also recently emerged as important regulators of cancer development and progression. They act by targeting multiple
signaling pathways including the TGF-β signaling pathway. There is growing evidence demonstrating that
miRNAs target various components of the TGF-β signaling pathway, including TGF-β1, TGF-β2, regulatory
SMADs (SMAD1, 2, 3, 5 and 9), co-mediator SMAD4, inhibitory SMADs (SMAD6 and 7) and the TGF-β receptors,
and thereby alter the proliferation and migration of CRC cells. In this review, we summarize the data
concerning the interaction between TGF-β signaling pathway and miRNAs with the aim to better understanding
the CRC molecular mechanisms and hence better management of this disease.
Keywords: SLCO1B1, atorvastatin, safety, lipid-lowering effects, meta-analysis, colorectal cancer.
Rights & PermissionsPrintExport